CoChat

MRI Outperforms [18F]AV‐1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy

Open access
Whitwell, Jennifer L., Tosakulwong, Nirubol, Schwarz, Christopher G., Botha, Hugo, Senjem, Matthew L., Spychalla, Anthony J., Ahlskog, J. Eric, Knopman, David S., Petersen, Ronald C., Jack, Clifford R., Lowe, Val J., Josephs, Keith A. · 2019 · Movement Disorders
Cited by 51

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Background: Elevated uptake of the [18 F]AV‐1451 tau‐PET ligand has been observed cross‐sectionally in subjects with progressive supranuclear palsy (PSP). However, it is unknown how the ligand performs longitudinally in PSP. We aimed to determine how regional measures of change on [18 F]AV‐1451 PET perform as longitudinal biomarkers of PSP compared with the more established biomarker of rate of midbrain atrophy. Methods: Sixteen subjects with PSP underwent 2 serial [18 F]AV‐1451 tau‐PET scans and 3‐Tesla MRI over 12 months and were age‐ and sex‐matched to 39 healthy controls with longitudinal [18 F]AV‐1451 PET. Median [18 F]AV‐1451 uptake was calculated for each scan for regions of interest across the brain and divided by uptake in cerebellar crus to create standard uptake value ratios. Midbrain volume on MRI was also calculated for each scan. Sample sizes required to power placebo‐controlled treatment trials were calculated. Results: Rate of midbrain atrophy was significantly increased in PSP compared with controls. [18 F]AV‐1451 regional change measures were significantly increased in PSP compared with controls in the pallidum, precentral cortex, dentate nucleus of the cerebellum, and midbrain. Change over time in the PSP Rating Scale correlated with change in midbrain volume but did not correlate with change in the [18 F]AV‐1451 measures. Smallest sample‐size estimates were obtained with rate of midbrain atrophy, followed by the PSP Rating Scale, with both outperforming [18 F]AV‐1451 measures. Conclusions: [18 F]AV‐1451 tau‐PET measures increase over time in subjects with PSP, but longitudinal [18 F]AV‐1451 measures may not perform as well as rate of midbrain atrophy as biomarkers for PSP clinical trials. © 2018 International Parkinson and Movement Disorder Society

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mds.27546

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 51

Metadata

Authors
Whitwell, J. L., Tosakulwong, N., Schwarz, C. G., Botha, H., Senjem, M. L., Spychalla, A. J., Ahlskog, J. E., Knopman, D. S., Petersen, R. C., Jack, C. R., Lowe, V. J., & Josephs, K. A.
Venue
Movement Disorders
Publisher
Wiley
Published
2018-11-23
Volume
34
Issue
1
Pages
105-113
ISSN
  • 0885-3185 (ISSN-L)
  • 1531-8257
OpenAlex
W2901938238
Cited by
51
References
14
FWCI
2.96
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MRI Outperforms [18F]AV‐1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. https://app.cochat.ai/papers/10.1002/mds.27546
The paper
Whitwell, J. L., Tosakulwong, N., Schwarz, C. G., Botha, H., Senjem, M. L., Spychalla, A. J., Ahlskog, J. E., Knopman, D. S., Petersen, R. C., Jack, C. R., Lowe, V. J., & Josephs, K. A. (2019). MRI Outperforms [18F]AV‐1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. Movement Disorders. https://doi.org/10.1002/mds.27546

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.